Cyfra (Ca) 21-1 near me in Ranchi
The Cyfra (Ca) 21-1 test is a blood test that measures the level of cytokeratin 19 fragments, a protein released into the blood from damaged or cancerous lung cells. This test is primarily used as a tumor marker to help in the detection and monitoring of lung cancer, particularly non-small cell lung carcinoma (NSCLC). It is widely available in Ranchi with Tata 1mg labs at an affordable price.
Doctors may recommend the CYFRA 21-1 test when there are symptoms suggestive of lung cancer, such as a persistent cough, chest pain, or difficulty breathing. It may also be advised for individuals at high risk of developing lung cancer due to factors like a history of smoking or occupational exposure. Additionally, the test is commonly used for patients who have already been diagnosed with lung cancer to monitor treatment effectiveness and detect any recurrence. Beyond lung cancer, CYFRA 21-1 can help evaluate other conditions that affect lung cancer biomarkers, providing valuable information for ongoing clinical assessment and management.
No special preparation is required for the Cyfra (Ca) 21-1 test. However, provide a brief clinical history at the time of sample collection. Inform a doctor about all the medications and supplements and underlying illnesses, as all these factors may affect the test results.
YES (1)
NO 
- Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 1995 Jul;108(1):163-9. [Accessed 27 Sep. 2025]. Available from:
- A deeper evaluation of cytokeratin fragment 21-1 as a lung cancer tumor marker and comparison of different assays [Internet]. ScienceDirect; [Accessed 27 Sep. 2025]. Available from:
- Miyadera K, Kakuto S, Sugai M, Tsugitomi R, Amino Y, Uchibori K, Yanagitani N, Sugiura H, Seike M, Nishio M, Ariyasu R. Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2024 Nov 4;16(21):3712. [Accessed 27 Sep. 2025]. Available from:
